Harbor Capital Advisors’s Freeline Therapeutics Holdings FRLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-20,352
Closed -$129K – 881
2023
Q4
$129K Buy
20,352
+7,848
+63% +$42K 0.02% 403
2023
Q3
$53K Buy
12,504
+1,795
+17% +$7.1K 0.01% 432
2023
Q2
$27.6K Buy
10,709
+3,527
+49% +$13.9K 0.01% 546
2023
Q1
$49.6K Sell
7,182
-1,429
-17% -$11.1K 0.01% 245
2022
Q4
$64.3K Sell
8,611
-186
-2% -$1.77K 0.06% 154
2022
Q3
$92K Sell
8,797
-974
-10% -$12.7K 0.08% 87
2022
Q2
$129K Buy
9,771
+126
+1% +$1.62K 0.1% 148
2022
Q1
$162K Sell
9,645
-2,523
-21% -$46.8K 0.08% 128
2021
Q4
$360K Buy
+12,168
New +$497K 0.13% 91

Harbor Capital Advisors's FRLN Position: Q1 2024 in Review

Harbor Capital Advisors sold out of Freeline Therapeutics Holdings (FRLN) in Q1 2024, closing a stake of 20,352 shares — an estimated $129K sold.

Harbor Capital Advisors first reported a position in FRLN in Q4 2021 and held it in 9 quarters. The position peaked at $360K in Q4 2021. 0 funds tracked by Wall St. Rank hold FRLN as of Q1 2024.

  • Harbor Capital Advisors reported no remaining Freeline Therapeutics Holdings position as of Q1 2024 after selling out during the quarter.
  • Harbor Capital Advisors sold 20,352 Freeline Therapeutics Holdings shares in Q1 2024, an estimated $129K.
  • Harbor Capital Advisors first reported a position in Freeline Therapeutics Holdings in Q4 2021 and held it in 9 quarters.
  • Harbor Capital Advisors's Freeline Therapeutics Holdings position peaked at $360K in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings as of Q1 2024.

Based on Harbor Capital Advisors's 13F filing for Q1 2024, filed 13 May 2024.